When large amounts of blood are collected, low red blood cell count (anemia) can develop. 12.4.1.6 Other Risks Risks include the possible occurrence of any of a range of side effects which are listed in the Consent Document or this protocol document. Frequent monitoring for adverse effects will help to minimize the risks associated with administration of the study agents. 12.4.2 Benefits The potential benefit to a patient that goes onto study is a reduction in the bulk of their tumor which may or may not have favorable impact on symptoms and/or survival. 12.4.3 Assessment of Potential Risks and Benefits Metastatic or refractory/recurrent HPV associated malignancies (cervical, anal, oropharyngeal cancers , etc.) are in need of improved therapy options . Preclinical studies suggest that the use of a combination of multiple immunotherapy agents may have improved anti- tumor efficacy. A number of clinically appropriate strategies to minimize risk s to participants have been built into the protocol through the means of inclusion/exclusion criteria, monitoring strategies, and management guidelines. Overall, the re is direct potential benefit of the combination of a therapeutic vaccine against HPV positive cancers (PDS0101), a tumor targeted immunocytokine (NHS -IL12) and a bifunctional fusion protein targeting PD -L1 and TGF beta (M7824) in subjects with advanced HPV associated malignancies for participants retaining the ability to consent and those who lose capacity to consent during the course of the trial with this combination immunotherapy proposed in this study. The potential benefit to a participant that goes onto this study is a reduction in the bulk of their tumor which may or may not have favorable impact on symptoms and/or survival.